Clinical Trial Update: Phase 2a Obesity Study of Oral Doses of Oleoyl-Estrone (MP-101) [Phase 2]

View source ↗

Summary

Phase 2a clinical trial of oral MP-101 (oleoyl-estrone) for obesity is being conducted by Manhattan Pharmaceuticals; the current status of the study is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Obesity

Drugs mentioned

• Oleoyl-Estrone (MP-101) (oleoyl-estrone)

Snippet

Sponsor: Manhattan Pharmaceuticals | Conditions: Obesity | Phase 2 | Status: UNKNOWN